Researchers for a large-scale retrospective cohort study have found a significant association between semaglutide use and an increased long-term risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with diabetes. They analyzed data from more than 3 million patients with diabetes and found that there was no increased risk within the first year, but from year 2 onward, semaglutide users exhibited a significantly heightened risk of NAION. Exclusive semaglutide use was linked to elevated risk. Variations in risk were observed across subgroups, including age, sex, race, comorbidities, and GLP-1 RA medication. Further research is needed to explore this association.

Source: JAMA Ophthalmology